BrainStorm CEO to Discuss Phase 3b ALS Trial at Maxim Healthcare Virtual Summit
BrainStorm CEO to Discuss Phase 3b ALS Trial at Maxim Healthcare Virtual Summit
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 Maxim Healthcare Virtual Summit. Chaim Lebovits, President and CEO of BrainStorm, will join Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, for a Fireside Chat at 9:30 a.m. ET on October 15. During the session, Mr. Lebovits will provide an update on the planned Phase 3b clinical trial for NurOwn, the company's investigational cell therapy for ALS. This event presents a valuable opportunity to engage with the investment community and share in-depth insights into the upcoming trial.
BrainStorm電芯治療公司（納斯達克股票代碼：BCLI）是一家領先的成人幹細胞治療方案開發商，專注於神經退行性疾病。今天宣佈將參加2024年Maxim Healthcare虛擬峯會。BrainStorm的總裁兼首席執行官Chaim Lebovits將與Maxim Group生物技術研究負責人、資深董事Jason McCarthy博士共同進行爐邊談話，時間爲美國東部時間上午9:30，日期爲10月15日。在此次會議中，Lebovits先生將介紹公司用於治療ALS的研究性細胞療法NurOwn計劃的階段3臨床試驗最新動向。這一活動爲與投資社區互動、分享即將啓動的試驗深入洞察提供了寶貴機會。
The Maxim Healthcare Summit will take place from October 15 to 17 and will bring together biotechnology, diagnostic, medical device, and healthcare information technology companies. Senior analysts will lead presentations and discussions, while engaging industry panels will focus on critical healthcare trends shaping the future of the industry.
Maxim Healthcare峯會將於10月15日至17日舉行，將彙集生物技術、診斷、醫療器械和醫療信息技術公司。資深分析師將主持演講和討論，同時參與行業專家小組將聚焦塑造行業未來的關鍵醫療趨勢。
